A historical study indicates that weight loss can approach obesity -related cancer.
Cancer experts said that the results were “transformative” and could promise “a complete new era of preventive cancer.”
Obesity is associated with 13 different cancers. While losing weight reduces this risk, scientists have calculated weight loss injections to a greater preventive effect and overrun the kilogram.
In Israel, researchers in Israel studied 6000 adults who have no previous history of cancer, who underwent surgery to treat obesity or took the bibli -1 pept x -1ras (saxenda) or exelatide (byetta) or Dujlutide (Truglutide). Medicines work by imitating the GLP-1 hormone in the body, which reduces blood sugar levels and makes people feel full for a longer period.
Although those who have undergone obesity surgery, it has been around the weight of those who have weight loss medications. TicketWhich was presented at the European Conference on Obesity in Malaga, Spain, which was published in the intermediate field in Lancet, found that the low risk of cancer is the same on a large scale.
The researchers said that obesity surgery reduces the risk of cancer by 30-42 %. Therefore, when calculating the relative feature of surgery in reducing patients’ weight, the authors found that weight loss medications were more effective in preventing obesity -related cancer.
“The preventive effects of the GLP-1ras against obesity-related cancers, they are likely to arise from multiple mechanisms, including reducing inflammation.
He added that the latest drugs can prove that they are more useful. “The new generation, which is very strong GLP-1ras, may be transmitted with a higher weight-reducing effectiveness, a greater advantage in reducing the risk of obesity-related cancer, but future research is needed to ensure that these drugs do not increase the risk of cancer non-obesity.”
separate TicketWhich was presented at the conference and published in the New England Journal of Medicine, directly compared Jabs to lose weight and found that patients who eat Mountjaro lost about 50 % of weight more than those who eat Wegovy. Patients in Mounjaro usually see a 20.2 % decrease in body weight at the end of the experiment compared to 13.7 % with Wegovy.
In response to the results, Professor Mark Luller, an expert in world -famous cancer research from Queen Belfast University, said while this was a observation -based study, and caution was needed to explain the results, and the results were very exciting.
“We already know that obesity surgery reduces the risk of obesity-related cancer. This data indicates that the target GLP-1 may reduce this risk by almost 50 %-a approach that may be a shift in preventing obesity-related cancer.
“From a biological point of view, this is logical, as targeting GLP-1 mixes inflammation, one of the distinctive features of cancer.
“Although more work is needed on how it works, this data raises interesting possibility that the GLP-1 can prevent multiple cancers in the general population, including common cancer such as breast and rectal, and difficulty in treating cancer such as pancreas and ovary. This work can raise a new complete era of preventive cancer.”
Professor Jason Hafford, former president of the European Society to study obesity The head of the University of Leeds, he said that medications should also be tested in patients with newly diagnosed cancer to see if they have strengthened the chances of survival.
He added that drugs have “the ability to be a new dawn. It is not only prevention, weight management in people who have recently been diagnosed with cancer is also very important in terms of results. This will be the next thing that must be seen. More and more cancer are related to obesity.”
A team of 54 international experts from 12 different countries issued a joint statement at the conference, calling for the experience of weight loss medications as a priority for cancer prevention. As a result, a team of UK scientists, based at the University of Manchester and the UK Cancer Research, is planning for a large -scale clinical experience that includes tens of thousands of patients, who hope to reach “three to five years”.
Dr. Matthew Harris, at the Manchester Cancer Research Center, said that JABS is a wonderful weight loss, and it may provide intervention that can be delivered on a population scale, as we have not been able to achieve this before.
